A bipartisan bill introduced in the Senate this week aims to address the growing issue of drug shortages.
A bipartisan bill introduced in the Senate this week aims to address the growing issue of drug shortages.
Introduced by Senators Susan Collins, R-Maine, and Tina Smith, D-Minnesota, the Mitigating Emergency Drug Shortages (MEDS) Act would give the FDA increased authority and expand manufacturing reporting requirements.
The bill was introduced the same day the FDA released the results of a task force, which spent about a year probing the causes of drug shortages as well as proposing some solutions. The report called the pharmaceutical marketplace “broken” and said that manufacturers need financial incentives to produce drugs at risk for shortage.
According to a statement from Collins’ office, the bill would:
The MEDS Act is supported by Premier, the American Hospital Association, the American Society of Anesthesiologists, the American Society of Clinical Oncology, the American Society of Health-Systems Pharmacists, and the Institute for Safe Medication Practices.
There were more than 200 shortages in 2018, the organizations said, and “The MEDS Act is a thoughtful, holistic and sustainable approach to eliminating drugs shortages,” said Blair Childs, senior vice president of public affairs of Premier, in a statement.
Collins’ office said drug shortages add $230 million a year to US drug costs and $216 million a year in increased labor costs as healthcare providers scramble to find an alternative source of medication.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.